Printer Friendly

WARNER-LAMBERT AND JOUVEINAL S.A. FORM RESEARCH-BASED ALLIANCE

 MORRIS PLAINS, N.J. and PARIS, Jan. 28 /PRNewswire/ -- Warner- Lambert Company (NYSE: WLA) and Jouveinal S.A., a privately held French pharmaceutical company, today announced the formation of a research based alliance.
 The agreement, which includes the acquisition by Warner-Lambert of a 34 percent interest in the Jouveinal Group, will enable both companies to participate in the global development of Jouveinal's promising compounds.
 Warner-Lambert's Chairman, Melvin R. Goodes, called the acquisition of a 34 percent interest in Jouveinal "a vital step in the company's strategy of building alliances in the growing pharmaceutical and consumer markets of Europe."
 "The combination of Jouveinal's leading-edge research especially in the field of gastroenterology and our worldwide reach gives us an outstanding opportunity to build on our mutual strengths," according to Lodewijk de Vink, Warner-Lambert's president and chief operating officer. Pointing out that the two companies have complementary marketing and research programs, de Vink termed the transaction "an exceptional investment opportunity and a model for future growth."
 Under this agreement Warner-Lambert has rights of first refusal to Jouveinal's developed compounds outside of France, its overseas departments and territories, French-speaking Africa and Canada.
 Mr. Ariel Elia, president of Jouveinal Laboratories, said that the partnership with Warner-Lambert "underlines its commitment to the worldwide development of its compounds. Jouveinal has consistently followed a growth strategy built on its core competencies in research, as evidenced by its recent award of the 1992 Prix Galien' for excellence in its research pipeline."
 Jouveinal 1992 sales grew 14 percent to more than FF 1 billion ($200 million) and is France's ninth largest pharmaceutical group. The company specializes in ethical and OTC pharmaceuticals, as well as fine chemicals and food flavors. Ethical pharmaceuticals generate 73 percent of its revenue, while over-the-counter medications account for 8 percent. Jouveinal is strongly committed to research, devoting 23 percent of its ethical pharmaceutical sales to R&D. One-fifth of its 1,000 people are involved in research. Its 1993 research budget will approach $40 million.
 Jouveinal's primary ethical products consist of Debridat (Trimebutine) for digestive problems, Pivalone, a nasal spray for allergic rhinitis, Claramid, an anti-infective and Eurobiol which is prescribed for pancreatic disorders. In the OTC market, Jouveinal's leading products are a dermatological antiseptic, a laxative and a motion sickness medication.
 Jouveinal's leading experimental product is fedotozine, which is being developed for non-ulcer related dyspepsia and irritable bowel syndrome. An antidepressant, Cericlamine, is seen as a viable therapy with fewer gastrointestinal disturbances than currently marketed products. A long-lasting glucocorticoid, Butixocort, has shown useful activity in the management of bronchial asthma.
 Warner-Lambert is a globalized company devoted to developing, manufacturing and marketing quality health care and consumer products with 1992 sales of $5.6 billion. The company's ethical pharmaceutical business is focused on the major therapeutic areas of cardiovascular disease, anticancer and anti-infective chemotherapy and central nervous system disorders. The company's broad range of consumer products includes over-the-counter pharmaceuticals, health care-related personal products, confectioneries including chewing gums and breath mints and shaving products including razors and blades. Warner-Lambert employs some 34,000 people in its operations in more than 130 countries.
 -0- 1/28/93
 /CONTACT: Peter Wolf, 201-540-6696, Stephen Mock, 201-540-6916, or Cary Rosansky, 201-540-4874 (analysts), all of Warner-Lambert; or Martine Konorski of Jouveinal S.A., 33-1-40-967565/
 (WLA)


CO: Warner-Lambert Company; Jouveinal S.A. ST: New Jersey IN: MTC SU:

WB -- NYTH005 -- 0100 01/28/93 09:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 28, 1993
Words:564
Previous Article:FIDUCIARY TRUST COMPANY REPORTS EARNINGS
Next Article:CARNEGIE MELLON DEMONSTRATES SPEECH TRANSLATION SYSTEM IN VIDEO CONFERENCE WITH RESEARCH PARTNERS IN GERMANY AND JAPAN
Topics:


Related Articles
WARNER-LAMBERT LAUNCHES MAJOR SMOKING CESSATION INITIATIVE; WELLNESS PROGRAM WILL ASSIST EMPLOYEES IN COPING WITH SMOKING RESTRICTIONS
WARNER-LAMBERT APPOINTS SURINDER KUMAR PRESIDENT, CONSUMER PRODUCTS R&D
WARNER-LAMBERT REPORTS SALES AND EARNINGS; 15 PERCENT EPS GAIN FOR 1992
WARNER-LAMBERT REPORTS FIRST-QUARTER SALES AND EARNINGS
WARNER-LAMBERT ACQUIRES FISONS' CONSUMER HEALTH BUSINESS IN AUSTRALIA AND NEW ZEALAND
SURINDER KUMAR ELECTED A WARNER-LAMBERT CORPORATE VICE PRESIDENT
WARNER-LAMBERT, WELLCOME ENTER OTC JOINT VENTURE
PARKE-DAVIS TO SPONSOR IOC OLYMPIC PRIZE
WARNER-LAMBERT REPORTS THIRD-QUARTER SALES AND EARNINGS
Warner-Lambert to Purchase Remaining Interest in Jouveinal

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters